RESPIRA Study for Pulmonary Arterial Hypertension

I'm Interested!

A Phase 2, Open-label, Dose Escalation Study to Evaluate the Safety and Efficacy of RT234 on Exercise Parameters Assessed by Cardiopulmonary Exercise Testing (CPET) in Subjects with Pulmonary Arterial Hypertension (PAH)

Sex at Birth: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase II
Conditions Being Studied: Pulmonary Arterial Hypertension ( PAH )

Study Purpose

The purpose of this study is to collect more information about the ability of RT234 to improve exercise capacity and safety of RT234 for the treatment of pulmonary arterial hypertension (PAH).

Who Can Participate

Age: 18-80

Principal Investigator
Robert Schilz DO

Department/Division
Medicine (Pulmonary and Critical Care Medicine)

Locations

UH Cleveland Medical Center
11100 Euclid Avenue
Cleveland OH, 44106

Get Directions

UH IRB: STUDY20211276
StudyID: 2021-0729
ClinicalTrials.gov: NCT04266197

I'm Interested!

Fill out our online form

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-800-641-2422